𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid

✍ Scribed by J. Atzpodien; H. Kirchner; S. Duensing; E. Lopez Hänninen; A. Franzke; J. Buer; M. Probst; P. Anton; H. Poliwoda


Publisher
Springer-Verlag
Year
1995
Tongue
English
Weight
353 KB
Volume
13
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Combination of alpha-interferon 2a (α-IF
✍ S. Toma; M. Airoldi; R. Palumbo; P. Raffo; C. Bumma 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 53 KB 👁 1 views

It is well known that survival of patients with advanced squamous-cell carcinoma of the head and neck (SCCHN) has not significantly improved despite recent advances in radiation and chemotherapy treatment. Specifically, a very low objective response rate can be obtained in patients with recurrent SC

Interleukin-2, interferon-α, 5-fluoroura
✍ Eliahu Gez; Raphael Rubinov; Diana Gaitini; Shimon Meretyk; Lael-Anson Best; Ofe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

## Abstract ## BACKGROUND The current study evaluated the efficacy and toxicity of interleukin‐2 (IL‐2), interferon‐α (IFN‐α), 5‐fluorouracil (5‐FU), and vinblastine (VBL) in the treatment of metastatic renal cell carcinoma (MRCC). ## METHODS Sixty‐two MRCC patients, median age 63 years, receive

Interferon-α-2a with or without 13-cis r
✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin

Induction of cell cycle arrest and apopt
✍ Xin Zhang; Zhuo (Georgia) Chen; Fadlo R. Khuri; Dong M. Shin 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 497 KB

## Abstract ## Background. We have previously conducted phase II trials with a combination of 13‐__cis__‐retinoic acid (13‐cRA), interferon‐α2a (IFN‐α2a), and α‐tocopherol (α‐TF) in patients with advanced oral premalignant lesions and locally advanced head and neck cancer in the adjuvant settings